Ista’s Xibrom Topical NSAID Approved For Cataract Surgery Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Ista's non-steroidal anti-inflammatory solution Xibrom gained an additional indication for treatment of pain following cataract surgery, the firm announced Jan. 30
You may also be interested in...
Ista Xibrom To Launch By Early June At Premium To Allergan Acular
FDA clears ophthalmic NSAID March 24 for postoperative inflammation following cataract surgery. Ista plans to complete scale-up of 70-rep sales force over the next several weeks, CEO Vince Anido says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.